IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases

What? ACR Study Group: Advances in Autoantibodies in Diagnosis and Management of Rheumatic Diseases

When & Where? Monday, October 22, 2018, 1:00-2:00pm, Room W178b, McCormick Place Convention Center, Chicago

Who? Autoantibody Standardization Committee

Coordinators: Edward K.L. Chan, PhD and Minoru Satoh, MD, PhD

Moderators: Luis Andrade, MD, PhD and Marvin Fritzler, PhD, MD

Session Overview: Immunofluorescence antinuclear antibody (ANA) assay (IFA) as the ‘gold standard’ autoantibody screening immunoassay was a major ACR position statement in 2009; later revised in 2011. Professors Pier Luigi Meroni, and Peter Schur were instrumental in this initiative and now Dr. Meroni, along with other speakers and attendees, will re-evaluate this paradigm and provide insights based on current evidence and practical laboratory protocols. Relevant clinical cases will be presented to support view points. The importance for practicing rheumatologists, clinical immunology laboratories, and the diagnostic industry will be discussed. Various evidence-based approaches to ANA and ANA subset autoantibody testing appropriate for different clinical settings will be discussed, including cost-effectiveness and value-based perspectives.

Speakers:

Pier Luigi Meroni, MD, University of Milan
Validity of IFA as the “gold standard” for ANA screening?
*Time: 1:00 - 1:15 pm + 5 minutes for questions*

Stanley Naides, MD, Quest Diagnostics Nichols Institute
Practical autoantibody screening strategy in a high throughput clinical laboratory
*Time: 1:20 – 1:35 pm + 5 minutes for questions*

Mark H. Wener, MD, University of Washington
Combined ANA immunofluorescence & ANA subset testing. Why not take the best of both?
*Time: 1:40 - 1:55 pm + 5 minutes for questions*